Kenneth E Sherman1, Susan D Rouster2, Minhee Kang3, Triin Umbleja3, Richard Sterling4,5, Adeel A Butt6. 1. Division of Digestive Diseases, University of Cincinnati College of Medicine, 231 Albert Sabin Way, Cincinnati, OH, 45267-0595, USA. Kenneth.sherman@uc.edu. 2. Division of Digestive Diseases, University of Cincinnati College of Medicine, 231 Albert Sabin Way, Cincinnati, OH, 45267-0595, USA. 3. Harvard TH Chan School of Public Health, Boston, MA, USA. 4. Weill Cornell Medical College, New York, NY, USA. 5. , Doha, Qatar. 6. Virginia Commonwealth University, Richmond, VA, USA.
Abstract
BACKGROUND AND AIMS: The patatin-like phospholipase domain-containing 3 (PNPLA3) gene has been associated with the development of alcoholic and nonalcoholic steatohepatitis. Using a newly developed and validated assay for PNPLA3, we explored the prevalence of gene polymorphisms in a cohort of HCV/HIV-coinfected individuals to determine whether there was an association with insulin resistance or hepatic fibrosis. METHODS: A high-resolution melting point (HRM) assay was developed and validated. The assay was used to evaluate samples obtained in the context of a clinical trial performed at ACTG sites across the USA in HIV-infected patients. Clinical features and treatment outcomes were assessed in relation to the PNPLA3 genotype. RESULTS: The HRM methodology demonstrated 100% concordance with results obtained by Sanger sequencing. Among 241 participants tested, 66.0% had the wild-type allele (CC) and the remainder had the aberrant PNPLA3 gene polymorphism in the homozygotic (GG) or heterozygotic (CG) form. Race and ethnicity were associated with PNPLA3 genotype but fibrosis stage, Homeostatic Model Assessment of Insulin Resistance, and HCV treatment outcome were not. CONCLUSION: The HRM method is an effective, rapid technique for characterizing PNPLA3 genotype. In those with HCV/HIV infection, nearly 40% carry gene polymorphisms associated with the development of NASH or ASH. Prospective studies should focus on this group to determine whether they represent a subset of HIV-infected persons at increased risk of fibrotic progression.
BACKGROUND AND AIMS: The patatin-like phospholipase domain-containing 3 (PNPLA3) gene has been associated with the development of alcoholic and nonalcoholic steatohepatitis. Using a newly developed and validated assay for PNPLA3, we explored the prevalence of gene polymorphisms in a cohort of HCV/HIV-coinfected individuals to determine whether there was an association with insulin resistance or hepatic fibrosis. METHODS: A high-resolution melting point (HRM) assay was developed and validated. The assay was used to evaluate samples obtained in the context of a clinical trial performed at ACTG sites across the USA in HIV-infectedpatients. Clinical features and treatment outcomes were assessed in relation to the PNPLA3 genotype. RESULTS: The HRM methodology demonstrated 100% concordance with results obtained by Sanger sequencing. Among 241 participants tested, 66.0% had the wild-type allele (CC) and the remainder had the aberrant PNPLA3 gene polymorphism in the homozygotic (GG) or heterozygotic (CG) form. Race and ethnicity were associated with PNPLA3 genotype but fibrosis stage, Homeostatic Model Assessment of Insulin Resistance, and HCV treatment outcome were not. CONCLUSION: The HRM method is an effective, rapid technique for characterizing PNPLA3 genotype. In those with HCV/HIV infection, nearly 40% carry gene polymorphisms associated with the development of NASH or ASH. Prospective studies should focus on this group to determine whether they represent a subset of HIV-infected persons at increased risk of fibrotic progression.
Entities:
Keywords:
AIDS; Fibrosis; Human immunodeficiency; Patatin-like; Steatosis
Authors: Richard K Sterling; Eduardo Lissen; Nathan Clumeck; Ricard Sola; Mendes Cassia Correa; Julio Montaner; Mark S Sulkowski; Francesca J Torriani; Doug T Dieterich; David L Thomas; Diethelm Messinger; Mark Nelson Journal: Hepatology Date: 2006-06 Impact factor: 17.425
Authors: Shivakumar Chitturi; Shehan Abeygunasekera; Geoffrey C Farrell; Jane Holmes-Walker; Jason M Hui; Caroline Fung; Rooshdiya Karim; Rita Lin; Dev Samarasinghe; Christopher Liddle; Martin Weltman; Jacob George Journal: Hepatology Date: 2002-02 Impact factor: 17.425
Authors: Felix Stickel; Stephan Buch; Katharina Lau; Henriette Meyer zu Schwabedissen; Thomas Berg; Monika Ridinger; Marcella Rietschel; Clemens Schafmayer; Felix Braun; Holger Hinrichsen; Rainer Günther; Alexander Arlt; Marcus Seeger; Sebastian Müller; Helmut Karl Seitz; Michael Soyka; Markus Lerch; Frank Lammert; Christoph Sarrazin; Ralf Kubitz; Dieter Häussinger; Claus Hellerbrand; Dieter Bröring; Stefan Schreiber; Falk Kiefer; Rainer Spanagel; Karl Mann; Christian Datz; Michael Krawczak; Norbert Wodarz; Henry Völzke; Jochen Hampe Journal: Hepatology Date: 2010-12-07 Impact factor: 17.425
Authors: Nicola Santoro; Romy Kursawe; Ebe D'Adamo; Daniel J Dykas; Clarence K Zhang; Allen E Bale; Anna M Calí; Deepak Narayan; Melissa M Shaw; Bridget Pierpont; Mary Savoye; Derek Lartaud; Samuel Eldrich; Samuel W Cushman; Hongyu Zhao; Gerald I Shulman; Sonia Caprio Journal: Hepatology Date: 2010-10 Impact factor: 17.425
Authors: Jennifer C Price; Eric C Seaberg; Rachel Latanich; Matthew J Budoff; Lawrence A Kingsley; Frank J Palella; Mallory D Witt; Wendy S Post; Chloe L Thio Journal: Am J Gastroenterol Date: 2014-03-18 Impact factor: 10.864
Authors: Kenneth E Sherman; Minhee Kang; Richard Sterling; Triin Umbleja; Kristen Marks; Jennifer J Kiser; Beverly Alston-Smith; Wayne Greaves; Adeel A Butt Journal: World J Hepatol Date: 2017-02-08
Authors: Kenneth E Sherman; Susan D Rouster; Heidi Meeds; Javier Tamargo; Jun Chen; Richard Ehman; Marianna Baum Journal: Biology (Basel) Date: 2021-03-21